Milestone Pharmaceuticals (NASDAQ:MIST) Receives Buy Rating from HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 289.29% from the company’s current price.

MIST has been the topic of a number of other reports. Wells Fargo & Company boosted their price target on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Monday, December 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Milestone Pharmaceuticals Trading Up 1.7%

Shares of MIST traded up $0.04 during midday trading on Tuesday, hitting $2.06. 1,515,333 shares of the stock were exchanged, compared to its average volume of 2,364,054. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $3.06. The stock has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $1.96. The firm has a market cap of $175.02 million, a P/E ratio of -2.51 and a beta of 0.44. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. On average, research analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new position in Milestone Pharmaceuticals during the 3rd quarter worth approximately $803,000. Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at $1,333,000. Bank of America Corp DE lifted its position in shares of Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth $6,444,000. Finally, Two Sigma Investments LP acquired a new position in shares of Milestone Pharmaceuticals during the third quarter worth $1,333,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.